Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA

Descripción del Articulo

Objetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic dia...

Descripción completa

Detalles Bibliográficos
Autores: Luna-Abanto, Luciana Isabel, Yan-Quiroz, Edgar Fermín
Formato: artículo
Fecha de Publicación:2021
Institución:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Repositorio:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Lenguaje:español
OAI Identifier:oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/872
Enlace del recurso:https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872
Nivel de acceso:acceso abierto
Materia:Sobrevida
Neoplasias del Cuello Uterino
Pronósticos
Quimioradioterapia
Survival
Uterine Cervical Neoplasms
Prognostic
Chemoradiotherapy
id REVCMH_286a831b6345077d3f630988fb9ee8ad
oai_identifier_str oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/872
network_acronym_str REVCMH
network_name_str Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
repository_id_str
dc.title.none.fl_str_mv Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
Valor del hemograma automatizado pretratamiento como predictor de sobrevida a 5 años en cáncer de cuello uterino estadio clínico IIB – IVA
title Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
spellingShingle Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
Luna-Abanto, Luciana Isabel
Sobrevida
Neoplasias del Cuello Uterino
Pronósticos
Quimioradioterapia
Survival
Uterine Cervical Neoplasms
Prognostic
Chemoradiotherapy
title_short Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
title_full Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
title_fullStr Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
title_full_unstemmed Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
title_sort Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA
dc.creator.none.fl_str_mv Luna-Abanto, Luciana Isabel
Yan-Quiroz, Edgar Fermín
author Luna-Abanto, Luciana Isabel
author_facet Luna-Abanto, Luciana Isabel
Yan-Quiroz, Edgar Fermín
author_role author
author2 Yan-Quiroz, Edgar Fermín
author2_role author
dc.subject.none.fl_str_mv Sobrevida
Neoplasias del Cuello Uterino
Pronósticos
Quimioradioterapia
Survival
Uterine Cervical Neoplasms
Prognostic
Chemoradiotherapy
topic Sobrevida
Neoplasias del Cuello Uterino
Pronósticos
Quimioradioterapia
Survival
Uterine Cervical Neoplasms
Prognostic
Chemoradiotherapy
description Objetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic diagnosis of clinical stage IIB-IVA cervical cancer treated with chemoradiotherapy treated at the Medical Oncology service at the Virgen de la Puerta High Complexity Hospital during the period 2015-2017. Results: The mean age of the patients was 51.78 ± 12.06 years (Range: 32-77 years). The average tumor size was 5.55 ± 1.33 cm (Range: 3 - 9 cm). Regarding the clinical stage according to the FIGO classification, it was found that 77.7% was classified as stage IIB, 20.8% as IIIB and 2.1% had a diagnosis of stage IVA cervical cancer. Univariate analysis found that anemia, leukocytosis, thrombocytosis, neutrophil / lymphocyte index, neutrophilia, and high platelet / lymphocyte index are not predictors of 5-year actuarial survival (p> 0.05), in terms of disease-free survival at 5 years it was found that anemia, leukocytosis and pretreatment neutrophil / lymphocyte index showed a trend towards significance (p = 0.05-0.1) and pretreatment neutrophilia is a predictor of 5-year disease-free survival, being statistically significant (0% vs 38.9%, p = 0.026). Conclusion: Pretreatment neutrophilia (> 7,500 μL) is a prognostic factor for 5-year disease-free survival in patients with clinical stage IIB-IVA cervical cancer undergoing chemoradiotherapy
publishDate 2021
dc.date.none.fl_str_mv 2021-05-21
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872
10.35434/rcmhnaaa.2021.141.872
url https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872
identifier_str_mv 10.35434/rcmhnaaa.2021.141.872
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872/404
dc.rights.none.fl_str_mv Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quiroz
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quiroz
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo
publisher.none.fl_str_mv Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo
dc.source.none.fl_str_mv Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 40 - 47
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 40 - 47
2227-4731
2225-5109
reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instacron:HNAAA
instname_str Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instacron_str HNAAA
institution HNAAA
reponame_str Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
collection Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1844532285346414592
spelling Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVAValor del hemograma automatizado pretratamiento como predictor de sobrevida a 5 años en cáncer de cuello uterino estadio clínico IIB – IVALuna-Abanto, Luciana IsabelYan-Quiroz, Edgar FermínSobrevidaNeoplasias del Cuello UterinoPronósticosQuimioradioterapiaSurvivalUterine Cervical NeoplasmsPrognosticChemoradiotherapyObjetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic diagnosis of clinical stage IIB-IVA cervical cancer treated with chemoradiotherapy treated at the Medical Oncology service at the Virgen de la Puerta High Complexity Hospital during the period 2015-2017. Results: The mean age of the patients was 51.78 ± 12.06 years (Range: 32-77 years). The average tumor size was 5.55 ± 1.33 cm (Range: 3 - 9 cm). Regarding the clinical stage according to the FIGO classification, it was found that 77.7% was classified as stage IIB, 20.8% as IIIB and 2.1% had a diagnosis of stage IVA cervical cancer. Univariate analysis found that anemia, leukocytosis, thrombocytosis, neutrophil / lymphocyte index, neutrophilia, and high platelet / lymphocyte index are not predictors of 5-year actuarial survival (p> 0.05), in terms of disease-free survival at 5 years it was found that anemia, leukocytosis and pretreatment neutrophil / lymphocyte index showed a trend towards significance (p = 0.05-0.1) and pretreatment neutrophilia is a predictor of 5-year disease-free survival, being statistically significant (0% vs 38.9%, p = 0.026). Conclusion: Pretreatment neutrophilia (> 7,500 μL) is a prognostic factor for 5-year disease-free survival in patients with clinical stage IIB-IVA cervical cancer undergoing chemoradiotherapyObjetivo: Identificar el valor del hemograma automatizado pretratamiento como predictor de sobrevida actuarial y sobrevida actuarial libre de enfermedad a 5 años en pacientes con cáncer de cuello uterino estadio clínico IIB-IVA. Material y Métodos: Análisis de sobrevida que evaluó a 48 pacientes con diagnóstico anatomopatológico de cáncer de cuello uterino estadio clínico IIB-IVA tratadas con quimioradioterapia atendidas en el servicio de Oncología Médica en el Hospital de Alta Complejidad Virgen de la puerta durante el periodo 2015-2017. Resultados: La edad media de las pacientes fue 51,78 ± 12,06 años (Rango: 32-77 años). El tamaño tumoral promedio fue de 5,55 ± 1,33 cm (Rango: 3 – 9 cm). En cuanto al estadio clínico según la clasificación FIGO se encontró que el 77,7% fue catalogada como estadio IIB, 20,8% como IIIB y el 2,1% tuvo diagnóstico de cáncer de cérvix estadio IVA. En el análisis univariado se encontró que la anemia, leucocitosis, trombocitosis, índice neutrófilo/linfocito, neutrofilia e índice plaquetas/linfocitos alto no son predictores de sobrevida actuarial a 5 años (p>0,05), en cuanto a la sobrevida libre de enfermedad a 5 años se encontró que la anemia, leucocitosis e índice neutrófilo/linfocito pretratamiento presentaron una tendencia a la significancia (p=0,05-0,1) y la neutrofilia pretratamiento es un predictor de sobrevida libre de enfermedad a 5 años siendo estadísticamente significativo (0% vs 38,9%, p=0,026). Conclusión: La neutrofilia pretratamiento (>7500 μL) es un factor pronóstico de sobrevida libre de enfermedad a 5 años en pacientes con cáncer de cuello uterino estadio clínico IIB-IVA sometidas a quimioradioterapia.Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo2021-05-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/87210.35434/rcmhnaaa.2021.141.872Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 40 - 47Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 40 - 472227-47312225-5109reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstacron:HNAAAspahttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872/404Derechos de autor 2021 Luciana Isabel Luna-Abanto, Edgar Fermín Yan-Quirozinfo:eu-repo/semantics/openAccessoai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/8722022-02-01T00:21:01Z
score 13.408957
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).